Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 982.29 +14.31 (+1.48%) Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 Next > Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO October 15, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA October 05, 2023 First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases October 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading September 19, 2023 Via Investor Brand Network Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading September 08, 2023 Via Investor Brand Network Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review September 29, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023 September 28, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review September 26, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss September 25, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Are Gene Therapy Stocks The Market's Next Big Winners? September 25, 2023 Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Argenx's 28% Surge & Promising Product Propel Investor Confidence September 25, 2023 Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. Via MarketBeat Regeneron Provides Update on Planned Chief Financial Officer Transition September 08, 2023 Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Updates to Board of Directors September 08, 2023 Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - August 31, 2023 From Brodsky & Smith LLC Via GlobeNewswire Regeneron Announces Investor Conference Presentations August 23, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention August 22, 2023 Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) August 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease August 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma August 17, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 Strong Biotech Performers To Watch As Sector Nears Breakout August 17, 2023 As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. Via MarketBeat Topics ETFs BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX) August 15, 2023 From Brodsky & Smith LLC Via GlobeNewswire Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration August 10, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX) August 09, 2023 From Brodsky & Smith LLC Via GlobeNewswire Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs August 09, 2023 From Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc. Via GlobeNewswire Regeneron Reports Second Quarter 2023 Financial and Operating Results August 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation August 01, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS July 29, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 Biotech Stocks to Buy for Long-Term Gains July 13, 2023 The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. Via MarketBeat Topics ETFs Economy Exposures Interest Rates $1 Billion Deal For Moderna To Expand Product Pipeline in China July 06, 2023 Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher Via MarketBeat Topics ETFs Economy Exposures COVID-19 Economy Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023 June 29, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.